Continuous vs. Bolus Administration of NSAIDs After Laparoscopic Surgery for Multimodal Analgesia: Pilot Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Currently the prevalent approach to perioperative management of patients is ERAS (Enhanced Recovery After Surgery) concept. This approach includes numerous aspects, among which the perioperative use of multimodal analgesia takes one of the leading places. Within the ERAS guidelines all sorts of minimization of opioid analgesics use in schemes of postoperative analgesia are appreciated. Thus, new pharmacological approaches are being actively developed currently in order to achieve adequate analgesia and to minimize the use of this group of drugs. One of the most perspective trends within the multimodal analgesia concept is continuous infusion of non-steroidal anti-inflammatory drugs (NSAID). Up to date there are papers that both confirm the effectiveness of this method for maintaining adequate postoperative analgesia and show its limitations and deny the advantages of the continuous use of NSAID. Up to this time the main attention of the medical community was paid for such drugs as paracetamol and ketoprofen. Nevertheless, one of the most common and safe NSAID is ibuprofen. In spite of this, there are no studies that explore the effectiveness of the continuous infusion of this drug. Thus, the lack of even low-quality evidence led to setting up a study of effectiveness and safety of continuous infusion of ibuprofen in comparison to its bolus injection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \> 18 years old

• Elective laparoscopic surgery

• General anesthesia

• Signed informed consent from the patient to participate in the study

• RASS scale from -2 to +1 on admission to a surgical department or ICU

Locations
Other Locations
Russian Federation
City Clinical Hospital named after S.S. Yudin
RECRUITING
Moscow
Contact Information
Primary
Valery Likhvantsev, PhD
lik0704@gmail.com
+79036235982
Backup
Kristina Kadantseva, PhD
kristina161093@gmail.com
+79168306947
Time Frame
Start Date: 2025-05-05
Estimated Completion Date: 2026-11-20
Participants
Target number of participants: 100
Treatments
Active_comparator: NSAID bolus injection
Experimental: NSAID continuous infusion
Related Therapeutic Areas
Sponsors
Leads: Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology

This content was sourced from clinicaltrials.gov

Similar Clinical Trials